Esflurbiprofen/Mentha Oil(Esflurbiprofen/Mentha Oil) - 在研适应症：炎症，骨关节炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Esflurbiprofen/Peppermint oil、SFPP、艾司氟比洛芬/薄荷油

靶点-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病其他疾病

在研适应症

炎症骨关节炎

非在研适应症-

原研机构

Taisho Pharmaceutical Co., Ltd.

在研机构

Taisho Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (2015-09-28),

炎症骨关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C15H13FO2

InChIKeySYTBZMRGLBWNTM-JTQLQIEISA-N

CAS号51543-39-6

关联

4

项与 Esflurbiprofen/Mentha Oil 相关的临床试验

JPRN-jRCT2080221798 / Unknown status临床3期

A Long-Term Clinical Study of SFPP in Patients with Osteoarthritis

开始日期2012-05-25

申办/合作机构

Taisho Pharmaceutical Co., Ltd.

[+1]

JPRN-jRCT2080221651 / Unknown status临床3期

Phase3 Study of SFPP in Patients with Osteoarthritis of the knee (Randomized, Parallel Group, Active Comparator-Controlled Study)

开始日期2011-11-11

申办/合作机构

Taisho Pharmaceutical Co., Ltd.

[+1]

JPRN-jRCT2080220876 / Unknown status临床2期

Phase 2 Dose-finding, Double-blind Controlled Study of SFPP in Knee Osteoarthritis 2nd

开始日期2009-09-26

申办/合作机构

Taisho Pharmaceutical Co., Ltd.

100 项与 Esflurbiprofen/Mentha Oil 相关的临床结果

登录后查看更多信息

100 项与 Esflurbiprofen/Mentha Oil 相关的转化医学

登录后查看更多信息

100 项与 Esflurbiprofen/Mentha Oil 相关的专利（医药）

登录后查看更多信息

18

项与 Esflurbiprofen/Mentha Oil 相关的文献（医药）

2024-04-01·Bioorganic Chemistry

Chemical proteomics unveils that seventy flavors pearl pill ameliorates ischemic stroke by regulating oxidative phosphorylation

Article

作者: Norbo, Kelsang ; Zhu, Yanning ; Ma, Ruyun ; Dhondub, Lobsang ; Dai, Jianye ; Zhu, Chunyan ; Wu, Caisheng ; Zhou, Feng ; Gyaltsen, Kelsang

Ischemic stroke has high mortality and morbidity rates and is the second leading cause of death in the world, but there is no definitive medicine. Seventy Flavors Pearl Pill (SFPP) is a classic formula in Tibetan Medicine. Clinical practice has shown the attenuation effect of SFPP on blood pressure disorders, strokes and their sequelae and other neurological symptoms, but its mechanism remains to be elucidated. In this study, we established three animal models in vivo and three cell models to evaluate the anti-hypoxia, anti-ischemia, and reperfusion injury prevention effects of SFPP. Quantitative proteomics revealed that oxidative phosphorylation (OXPHOS) is essential for SFPP's efficacy. Then, cysteine-activity based protein profiling technology, which reflects redox stress at the proteome level, was employed to illustrate that SFPP brought functional differences of critical proteins in OXPHOS. In addition, quantitative metabolomics revealed that SFPP affects whole energy metabolism with OXPHOS as the core. Finally, we performed a compositional identification of SFPP to initially explore the components of potential interventions in OXPHOS. These results provide new perspectives and tools to explore the mechanism of herbal medicine. The study suggests that OXPHOS could be a potential target for further research and intervention of ischemic stroke treatment.

2023-10-01·Environmental and Molecular Mutagenesis

Assessment of the in vivo genotoxic potential of three smoke flavoring primary product mixtures

Article

作者: Franzen, Allison ; Blanchette, Alexander D ; Keig-Shevlin, Zena ; Thompson, Chad M ; Brorby, Gregory ; Doepker, Candace ; Ulrich, Kristina ; Smith, Robert

AbstractSmoke flavorings are mixtures generated from wood pyrolysis that are filtered to remove tar and are often considered healthier alternatives to conventional smoking processes. While the latter is mostly unregulated, smoke‐flavoring primary products (SFPPs) are undergoing the 10‐year required re‐evaluation in the European Union (EU). To comply with recent smoke flavor guidance, in vivo micronucleus studies in rats and transgenic rodent (TGR) mutation assays in Muta™Mice were conducted on three SFPPs. For most studies, typical limit doses were exceeded to comply with regulatory requests. Exposure to SFPPs by oral gavage did not result in significant increases in bone marrow micronucleus formation. Except for one group, exposure to SFPPs via feed for 28 days did not result in significant increases in mutant frequency (MF) in the glandular stomach or liver. One group exposed to a maximal feasible dietary dose of 50,000 ppm (>10,000 mg/kg bodyweight per day) exhibited a statistically significant increase in liver MF; however, the MF in all mice in this group were within the historical vehicle control 95% quantile confidence intervals and therefore not considered biologically relevant. Based on estimates of human dietary exposure to each SFPP, the margin of exposure (MOE) values in the TGR assays exceed 10,000. The MOE for one unintentionally present constituent, 2,5(H)‐furanone, also exceeds 10,000. Collectively, these data indicate that these SFPPs pose no genotoxic risk and are safe alternatives to conventional smoking.

2023-09-02·Cureus

Effectiveness and Adherence Rate of S-flurbiprofen Plaster for the Pain Management of Patients With Moderate and End-Stage Knee Osteoarthritis

Article

作者: Takeshita, Katsushi ; Takahashi, Tsuneari ; Iguchi, Masaki

BACKGROUNDS-flurbiprofen plaster (SFPP) is highly skin permeable and represents a new conservative treatment for knee osteoarthritis (KOA) that can attain considerably higher concentrations in the synovium than topical flurbiprofen. To date, no study has investigated the efficacy and adherence rate of SFPP in patients with end-stage KOA. This study aimed to compare the effectiveness and adherence rate of SFPP for pain management in patients with moderate and end-stage KOA.METHODSThis retrospective study included a total of 118 patients with KOA (Kellgren-Lawrence classification grades II (n = 29), III (n = 32), and IV (n = 57)). The difference in SFPP use rate, adverse drug reactions rate, whether 50% pain relief occurred, and the percentage of patients who underwent surgical treatment were calculated.RESULTSThe overall SFPP use rate at one year was 61.0% (88.1% at less than one month, 79.7% at three months, and 61.0% at six months), with no significant differences among Kellgren-Lawrence grade II, III, and IV groups (p = 0.538). Adverse drug reactions such as skin rash (n = 23), skin irritation (n = 8), and gastrointestinal disorders (n = 2) were observed. The one-year SFPP use rate was significantly lower in patients in whom these side effects occurred but did not decrease in patients in whom only a skin rash occurred. Overall, 19 patients underwent surgery after discontinuation of SFPP use. Surgery was statistically selected more by the "over 71 years of age" group (p = 0.038) and the "ineffective" group (p = 0.007).CONCLUSIONSFPP exerts a comparable therapeutic effect even in end-stage KOA and may be an effective treatment option. Even if patients have end-stage KOA, there are cases in which the patient's background does not allow for surgery positively, such as high perioperative risk or desire for conservative treatment. In such cases, SFPP may be an effective treatment option worth trying.

100 项与 Esflurbiprofen/Mentha Oil 相关的药物交易

登录后查看更多信息